Summit Therapeutics Inc. (SMMT) P/E Ratio History
Historical price-to-earnings valuation from 2018 to 2019
Loading P/E history...
SMMT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Summit Therapeutics Inc. (SMMT) trades at a price-to-earnings ratio of -11.9x, with a stock price of $17.15 and trailing twelve-month earnings per share of $-1.56.
The current P/E is 159% below its 5-year average of 20.3x. Over the past five years, SMMT's P/E has ranged from a low of 12.1x to a high of 34.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, SMMT trades at a 153% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SMMT trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SMMT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SMMT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $9B | 43.4 | - | +128%Best | |
| $12B | 16.6Lowest | 0.32Best | +58% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SMMT Historical P/E Data (2018–2019)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2019 Q1 | $1.77 | $0.12 | 14.4x | -29% | |
| FY2018 Q4 | $1.33 | $0.11 | 12.1x | -40% | |
| FY2018 Q2 | $2.30 | $0.07 | 34.4x | +69% |
Average P/E for displayed period: 20.3x
Full SMMT Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SMMT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SMMT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SMMT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSMMT — Frequently Asked Questions
Quick answers to the most common questions about buying SMMT stock.
Is SMMT stock overvalued or undervalued?
SMMT trades at -11.9x P/E, below its 5-year average of 20.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SMMT's valuation compare to peers?
Summit Therapeutics Inc. P/E of -11.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is SMMT's PEG ratio?
SMMT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2018-2019.